ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,796.00
0.34%
S&P ASX All Technology
3,092.40
0.70%
Brent Oil
84.39
0.00%
US Dollar vs AUD
1.49678
0.00%
Bitcoin
64,394.89
0.23%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Pfizer Inc (PFE)

  7. Pfizer Inc (PFE) News

PFE

Pfizer (PFE)

Pfizer Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:PFE
DateTimeSourceHeadlineSymbolCompany
19/06/202400:00Business WirePfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with AnalystsNYSE:PFEPfizer Inc
18/06/202421:02IH Market NewsFisker Files for Bankruptcy, Chegg Stocks Rise on 23% Workforce Reduction, and MoreNYSE:PFEPfizer Inc
18/06/202411:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
18/06/202411:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
14/06/202421:21IH Market NewsAdobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and MoreNYSE:PFEPfizer Inc
14/06/202417:00Business WireELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple MyelomaNYSE:PFEPfizer Inc
13/06/202406:30Business WirePfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular DystrophyNYSE:PFEPfizer Inc
12/06/202404:43Edgar (US Regulatory)Form 11-K - Annual report of employee stock purchase, savings and similar plansNYSE:PFEPfizer Inc
12/06/202404:39Edgar (US Regulatory)Form 11-K - Annual report of employee stock purchase, savings and similar plansNYSE:PFEPfizer Inc
10/06/202421:29IH Market NewsApple Showcases AI at WWDC 2024, Nvidia Stock Split Starts Today, and More NewsNYSE:PFEPfizer Inc
06/06/202406:05GlobeNewswire Inc.Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608NYSE:PFEPfizer Inc
05/06/202407:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
05/06/202407:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
04/06/202408:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
04/06/202400:00Business WirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceNYSE:PFEPfizer Inc
01/06/202422:00Business WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)NYSE:PFEPfizer Inc
01/06/202422:00Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:PFEPfizer Inc
01/06/202402:15Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:PFEPfizer Inc
31/05/202422:00Business WirePfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease ProgressionNYSE:PFEPfizer Inc
23/05/202421:40IH Market NewsOpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More NewsNYSE:PFEPfizer Inc
23/05/202402:39Edgar (US Regulatory)Form 8-K - Current reportNYSE:PFEPfizer Inc
17/05/202401:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
17/05/202401:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
16/05/202421:27IH Market NewsChubb Stock Soars 9% with Berkshire Acquisition, AST SpaceMobile jumps 37% on AT&T deal, and More NewsNYSE:PFEPfizer Inc
16/05/202420:00GlobeNewswire Inc.Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)NYSE:PFEPfizer Inc
13/05/202422:00PR Newswire (US)Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual MeetingNYSE:PFEPfizer Inc
13/05/202421:16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNYSE:PFEPfizer Inc
09/05/202423:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:PFEPfizer Inc
09/05/202421:53IH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:PFEPfizer Inc
09/05/202405:56Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:PFEPfizer Inc
 Showing the most relevant articles for your search:NYSE:PFE

Your Recent History

LSE
93TC
Newday 27 A
TG
DPWJ
Deutsche Post
LSE
55RZ
Res Mtg 23 41
EU
MTA
Amundi Euro Government B...
BIT
NSCIT2880978
IBRD
UNSW3
WAIFETH
Waifu
TG
BP45YQ
BNP Paribas Home Loan SFH
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved